Primary nasal Kaposi Sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use

Htet, Kyaw Zin; Waul, Michael; Edelstein, Howard; Mui, Stanley K.; Cherny, Sarah C.; Leslie, Kieron

doi:10.1177/0956462420980644

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, topical steroids, widely prescribed for rashes and available over the counter, may worsen Kaposi sarcoma because of their immunosuppressive effect. Another common practice that may harm patients who have Kaposi sarcoma is recommending intranasal steroids when they report nasal or sinus congestion, because incident upper airway Kaposi sarcoma and worsening of existing Kaposi sarcoma have been reported with long-term intranasal steroid use 62. Patients should be carefully assessed and the risk should be discussed with them if this treatment is deemed necessary.…”

Section: Management and Treatmentmentioning

confidence: 99%

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

Mangusan

Ekwede

Widell

2022

AJN, American Journal of Nursing

View full text Add to dashboard Cite

:Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus, also known as human herpesvirus 8. Its occurrence is associated with an immunocompromised state. Kaposi sarcoma that occurs among people living with HIV (PLWH) is known as epidemic Kaposi sarcoma. Despite the decline in HIV-associated complications because of the introduction of combination antiretroviral therapy two decades ago, Kaposi sarcoma continues to affect PLWH worldwide. It affects young African American men more than other age and racial groups and can result in multiorgan dysfunction, leading to short-term and chronic debilitating symptoms as well as death. While some patients with epidemic Kaposi sarcoma are managed as outpatients, others may require higher levels of care and their acuity may fluctuate throughout their life span. Therefore, nurses, regardless of their specialty, may experience caring for a patient with epidemic Kaposi sarcoma at some point in their career. Learning about this condition and the needs of patients who have it will help nurses provide effective care. Here, the authors describe Kaposi sarcoma in general as well as the epidemiology, characteristics, and management of epidemic Kaposi sarcoma. They also describe specific nursing considerations in the care of PLWH who have the disease.

show abstract

Section: Management and Treatmentmentioning

confidence: 99%

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

Mangusan

Ekwede

Widell

2022

AJN, American Journal of Nursing

View full text Add to dashboard Cite

show abstract

Fluticasone-propionate

2021

Reactions Weekly

View full text Add to dashboard Cite

Primary Kaposi’s Sarcoma of the Nasal Cavity: Clinical Experience and Review of the Literature

Xiang

Liu

et al. 2022

Ear Nose Throat J

View full text Add to dashboard Cite

Kaposi’s sarcoma (KS) is a vascular sarcoma derived from vascular endothelial cells and presents with multiple lesions. It mainly appears on the skin and oral mucosa, usually in the face, oral mucosa, and genitals. Very few cases of primary lesions in the nasal cavity have been reported. It is often difficult to diagnose only by imaging examination. Here, we describe a case of KS in a patient who was human immunodeficiency virus (HIV)-negative, in which the primary sites were the nasal mucosa and nasal septum. A diagnosis was made according to the patient’s clinical presentation, physical examination, laboratory examination, imaging examination, and histopathological results. We used surgical resection combined with chemotherapy, with 6 months’ postoperative follow-up without recurrence. We reviewed the relevant literature to identify similar cases and summarize the findings reported on this rare manifestation of KS. We recommend that, where possible, antiviral therapy such as interferon, and regular review should continue, to improve the survival rate and patients’ quality of life.

show abstract

Primary nasal Kaposi Sarcoma in well-controlled HIV-positive patient with normal CD4 count associated with long-term nasal steroid use

Cited by 4 publications

References 7 publications

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era

Fluticasone-propionate

Primary Kaposi’s Sarcoma of the Nasal Cavity: Clinical Experience and Review of the Literature

Contact Info

Product

Resources

About